A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?

J Hepatol. 2023 Oct;79(4):e154-e155. doi: 10.1016/j.jhep.2023.01.021. Epub 2023 Feb 1.

Authors

Sinead Carlson¹, Karl Vaz², Adam Peterson³

Affiliations

¹ Department of Gastroenterology, Monash Health, School of Clinical Sciences, Monash University, Australia. Electronic address: sinead.carlson@monashhealth.org.
² Department of Gastroenterology, Alfred Health, Central Clinical School, Monash University, Australia; Department of Gastroenterology, Austin Health, Australia.
³ Department of Gastroenterology, Monash Health, School of Clinical Sciences, Monash University, Australia.

PMID: 36736735
DOI: 10.1016/j.jhep.2023.01.021

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Hepatocellular* / pathology
DNA, Viral
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Hepatitis B virus / genetics
Hepatitis B* / complications
Hepatitis B, Chronic*
Humans
Liver Neoplasms* / pathology

Substances

Hepatitis B Surface Antigens
DNA, Viral
Hepatitis B e Antigens